e-space
Manchester Metropolitan University's Research Repository

A non-myeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma.

Yu, Kenny and Youshani, A Saam and Wilkinson, Fiona L and O'Leary, Claire and Cook, Peter and Laaniste, Liisi and Liao, Aiyin and Mosses, Dominic and Waugh, Christopher and Shorrock, Hannah and Pathmanaban, Omar and Macdonald, Andrew and Kamaly-Asl, Ian and Roncaroli, Federico and Bigger, Brian W (2019) A non-myeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma. Neuropathology and Applied Neurobiology, 45 (2). pp. 119-140. ISSN 0305-1846

[img]
Preview

Available under License Creative Commons Attribution Non-commercial.

Download (3MB) | Preview

Abstract

Resident and peripherally-derived glioma associated microglia/macrophages (GAMM) play a key role in driving tumour progression, angiogenesis, invasion, and attenuating host immune responses. Differentiating these cells' origins is challenging and current pre-clinical models such as irradiation-based adoptive transfer, parabiosis and transgenic mice have limitations. We aimed to develop a novel non-myeloablative transplantation (NMT) mouse model that permits high levels of peripheral chimerism without blood-brain barrier (BBB) damage or brain infiltration prior to tumour implantation.NMT dosing was determined in C57BL/6J or Pep3/CD45.1 mice conditioned with concentrations of busulfan ranging from 25mg/kg to 125mg/kg. Donor haematopoietic cells labelled with eGFP or CD45.2 were injected via tail vein. Donor chimerism was measured in peripheral blood, bone marrow and spleen using flow cytometry. BBB integrity was assessed with anti-IgG and anti-fibrinogen antibodies. Immunocompetent chimerised animals were orthotopically implanted with murine glioma GL-261 cells. Central and peripheral cell contributions were assessed using immunohistochemistry and flow cytometry. GAMM subpopulation analysis of peripheral cells was performed using Ly6C/MHCII/MerTK/CD64.NMT achieves >80% haematopoietic chimerism by 12 weeks without BBB damage and normal life span. Bone marrow derived cells (BMDC) and peripheral macrophages accounted for approximately 45% of the GAMM population in GL-261 implanted tumours. Existing markers such as CD45 high/low proved inaccurate to determine central and peripheral populations while Ly6C/MHCII/MerTK/CD64 reliably differentiated GAMM subpopulations in chimerised and unchimerised mice.NMT is a powerful method for dissecting tumour microglia and macrophage subpopulations and can guide further investigation of BMDC subsets in glioma and neuro-inflammatory diseases. This article is protected by copyright. All rights reserved.

Impact and Reach

Statistics

Downloads
Activity Overview
56Downloads
74Hits

Additional statistics for this dataset are available via IRStats2.

Altmetric

Actions (login required)

Edit Item Edit Item